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Summary
Objective: Oral glucosamine (GlcN) has been widely studied for its potential therapeutic beneﬁts in alleviating the pain and disability of oste-
oarthritis (OA). Its popularity has grown despite ongoing controversy regarding its effectiveness vs placebo in clinical trials, and lack of infor-
mation regarding possible mechanisms of action. Here, we review the state of knowledge concerning the biology of GlcN as it relates to OA,
and discuss a framework for future research directions.
Methods: An editorial ‘‘narrative’’ review of peer-reviewed publications is organized into four topics (1) Chemistry and pharmacokinetics of
GlcN salts (2) Biological effects of GlcN salts in vitro (3) Therapeutic effects of GlcN salts in animal models of OA and (4) GlcN salts in
the treatment of clinical OA.
Results: Data reporting potent pleiotropic activities of GlcN in in vitro cell and explant cultures are discussed in the context of the established
pharmacokinetic data in humans and animals. The available clinical trial data are discussed to place the patient in the context of controlled
research on disease management.
Conclusions: Future research to determine therapeutic mechanisms of GlcN salt preparations will require use of standardized and clinically
relevant in vitro assay systems and in vivo animal models for testing, as well as development of new outcome measures for inﬂammation and
pain pathways in human OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Oral glucosamine (GlcN) is widely used both in Europe and
in the US in an attempt to palliate the pain and disability of
osteoarthritis (OA), and is a component of a large number of
dietary supplements in the US. It has also garnered great
interest in the ﬁtness and athletics communities because
of claims that it has cartilage building and lubricant proper-
ties for the joints1. Its popularity has grown despite ongoing
controversy regarding its effectiveness (vs placebo), safety,
and possible mechanisms of action. While GlcN is highly
bioactive when added to cell cultures at supra-physiologic
concentrations, we conﬁne our discussion here to its puta-
tive effects on joint disease in vivo, speciﬁcally on pain,
mobility and structural protection.
The publication in 1996 of ‘‘The Arthritis Cure’’ by Jason
Theodosakis, M.D. stimulated interest by the American
public in oralGlcNasaneffective therapeutic forOA.Theodo-
sakis’ claims for therapeutic efﬁcacy were based largely on
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5The same author published an updated version in 2004
entitled ‘‘The Arthritis Cure: The Medical Miracle That Can
Halt, Reverse, and May Even Cure Osteoarthritis’’.2 These
books, along with widespread anecdotal reports of pain relief
achievedwith oral GlcN aswell as the absence of clearly safe
and effective therapies that retard OA progression, have
resulted in the GlcN market for OA and other joint conditions
(alone or in combination with other components such as
chondroitin sulfate) developing into a multi-billion dollar
industry in the US; a parallel industry has developed in
Europe, where GlcN is available as a prescription drug.
As a result of its popularity and its potential therapeutic
efﬁcacy, GlcN has been studied intensively, and there is
a great deal of information concerning its cellular mecha-
nism of action, animal and human pharmacokinetics and
clinical efﬁcacy. Most in vitro studies of GlcN activity on joint
tissue have been performed in the 50e5000 mM range,
although some studies have been done at as low as 1 mM
(see Table I) To serve as a comparison, in diabetes re-
search the effects of 2 mM GlcN on the ﬂux of glucose-de-
rived intermediates through the hexosamine biosynthetic
pathway (HBP) have been extensively evaluated. GlcN-
dependent alterations in the activity of O-glycosylated
intracellular signaling components, including increased
O-N-acetyl-glucosamination of factors such as IRS, GS,
PDX-1, eNOS and Sp1, have also been described3.
Table I
In vitro studies of GlcN effects on Cartilage and Chondrocytes
Pathways assayed Tissue or cell source Culture condition* Compound
[Concentration range]
Reference
Aggrecan, Collagen,
ECM synthesis
Murine, canine, porcine,
bovine, equine & human
chondrocytes Equine
synovial ﬁbroblasts
Human MSC
Monolayer cultures, alginate
bead cultures, IL-1b
GlcN.HCl [1 mMe25,000 mM]
GlcN.SO4 [50 mMe5000 mM]
27, 28, 40y, 41e49, 73
Protease production Equine and human
chondrocytes Equine
and human synoviocytes
Monolayer culturesþ
catabolic stimulators
(IL-1b or LPS)
GlcN.HCl [1 mMe6000 mM]
GlcN.SO4 [1000 mMe2500 mM]
40y, 47y, 50, 51
Inﬂammatory mediator
gene expression &
production
Canine, equine, human
chondrocytes Rat IVD
cells Equine & human
synoviocytes
Monolayer cultures, alginate
or agarose bead cultures,
IL-1b
GlcN.HCl [1 mMe25,000 mM]
GlcN.SO4 [50 mMe10,000 mM]
27, 47y, 48e55
Signal transduction Equine, human &ATDC5
chondrocytes; human
synovial ﬁbroblasts;
bovine chondrocytes
Monolayers IL-1b GlcN.HCl [60 mMe6000 mM]
GlcN.SO4 [50 mMe60 mM]
27, 51e53, 56, 73
Glucose transporters
& Ion channels
Bovine chondrocytes Monolayersþ IL-1b GlcN.HCl [1000 mMe2500 mM] 4, 6
Aggrecan degradation
ADAMTS proteinase
gene expression
Explants of bovine,
equine and human
OA cartilage
þCatabolic stimulators
(IL-1b, LPS, retinoic acid
& FN fragments)
GlcN.HCl [400 mMe5000 mM]
GlcN.SO4 [300 mMe7500 mM]
24e26, 42, 43, 57e72
MMP/TIMP gene and
protein expression
Explants of bovine,
equine and human
OA cartilage
þCatabolic stimulators
(IL-1b, LPS, FN fragments)
GlcN.HCl [30 mMe5000 mM]
GlcN.SO4 [60 mMe5000 mM]
59, 61e64, 67e69
Inﬂammatory mediator
gene expression and
production
Explants of bovine,
equine and human
OA cartilage
þCatabolic stimulators
(IL-1b & LPS)
GlcN.HCl [60 mMe5000 mM]
GlcN.SO4 [30 mMe5000 mM]
43, 62, 63, 65e70
ECM production Explants of bovine,
equine, porcine and
human OA cartilages
þCatabolic stimulators
(IL-1b, LPS, retinoic acid
& FN fragments)
GlcN.HCl [30 mMe5000 mM]
GlcN.SO4 [45 mMe5000 mM]
24, 25, 44, 58, 59,
63e69
*Note that for most studies Dulbecco’s modiﬁed Eagle medium (DMEM) containing 25,000 mM glucose is used as culture medium
yReferences 40 and 47 found an effect of GlcN at physiologically relevant concentrations. All other studies used test concentrations >30 mM
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have shown that the Cmax after recommended GlcN dosing
(1500 mg per day) is approximately 10 mM; this suggests
that the high concentrations that appear to be active in vitro
(Table I) are not physiologically relevant to the action of the
drug in the post-hepatic metabolism in vivo. Since O-glyco-
sylation of signaling factors also occurs only at supra-phys-
iologic concentrations3, this mechanism does not appear to
be relevant to the proposed actions of oral GlcN on joint tis-
sues either. Some groups have recently observed effects of
GlcN at in vitro concentrations in the 1e60 mM range40,47; if
conﬁrmed by independent laboratories, these studies might
provide insight into clinically relevant actions of this com-
pound on cell metabolism.
The sodium-independent facilitative glucose transpor-
ter4e6 provides the mechanism for both glucose and GlcNTable I
GlcN pharmacokinetics
Formulation Single dose (mg/kg/day) No of subjects enrolled Rout
GlcN.HCl 7 40 Oral
GlcN.SO4 20 20 Oral
GlcN.SO4 20 12 Oral
GlcN.SO4 20 12 Oral
GlcN.SO4 10 22 Oral
GlcN.SO4 20 12 Oral
GlcN.SO4 20 18 Oraluptake into cells. As the Km (extracellular concentration re-
quired for effective uptake) for both glucose and GlcN for
the functional chondrocyte transporter is about 350 mM,6
and the in vitro studies listed in Table I have almost exclu-
sively been performed in culture medium containing
25,000 mM of competing glucose, only a very small percent-
age (perhaps 1e2%) of the GlcN added to such cell and ex-
plant cultures is likely to enter the cells. Indeed, in studies
on this aspect of incorporation using exogenous GlcN con-
centrations of 50 mM (in the presence of 5500 mM glucose),
only about 5% of the exogenous GlcN entered intracellular
pathways that led to its activation to a high energy uridine
diphosphate (UDP)-derivatized intermediate for subsequent
usage by glycosyltransferases7e9. Therefore given our
present understanding of functional uptake mechanisms in
chondrocytes, the clinically relevant studies in vitro, i.e.,I
: human studies
e Days of dosing Cmax Serum/Plasma assay Reference
21 3e4 mM HPLC 81
1 12 mM LC/MS/MS 82
1e3 9 mM LC/MS/MS 83
14 7 mM LC/MS/MS 77
1 2 mM LC/MS/MS 84
1 10 mM LC/MS/MS 84
1 11 mM Amperometic 8
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less than 50 mM, will need to be evaluated in light of the pre-
vailing glucose concentration and the activity of the glucose
transporter mediating cellular uptake of GlcN.
Further, when considering the situation in vivo it is highly
likely that the intestinal lining, liver or kidney will consume
a substantially higher percentage of the orally administered
monosaccharide than joint tissues. This follows from the
fact that each of these tissues utilizes the GLUT-2 trans-
porter which has a Km of about 17,000 mM for glucose
and 800 mM for GlcN10. In light of these considerations,
this review seeks to evaluate objectively the current knowl-
edge of potential intracellular mechanisms of GlcN action,
focusing on those that might affect the joint following clini-
cally relevant dosing and a therapeutically relevant Cmax
In addition, we review the clinical data on GlcN to assess
the need for a re-evaluation of research efforts in this area.Chemistry of GlcN.HCl, GlcN.sulfate salt and
GlcN-3-sulfate ester
An important and often confusing aspect of GlcN usage
has been the structure of the various GlcN compounds mar-
keted for oral consumption. For example, claims have been
made both by suppliers and by medical authorities that
‘‘GlcN.sulfate’’ is superior to ‘‘GlcN.hydrochloride’’. However,
the only organic component in both formulations is the amino-
sugar GlcN, (C6H13NO5), and in this regard the formulations
are chemically and structurally identical, differing only in the
nature of the salt included to neutralize the proton on the
amino-group of the GlcN.Whereas in GlcN.HCl, it is the chlo-
ride salt (composition, [GlcNH3þ].Cl), for GlcN.sulfate it is
a mixture of the sulfate and the chloride salts (composition,
[GlcNH3þ]2.2Na
þ.SO4
2.2Cl) (US Patent No. 4,642,340).
When GlcN.HCl enters the human stomach (normally at pH
2.5 due to a high normal content of HCl) it dissociates com-
pletely to GlcN (the amino-sugar) and HCl (hydrochloric
acid); similarly, GlcN.sulfate dissociates to the amino-sugar,
HCl (hydrochloric acid), Na2SO4 (sodium sulfate) and H2SO4
(sulfuric acid). In other words, for each formulation, the only
organic ingredient upon oral consumption is GlcN itself.
The salts and acids generated, however, are different. On
the basis that GlcN is considered to be the active ingredient
in both formulations, there is no rationale available in the
scholarly literature that might explain superiority of one over
the other. Some9,11,12 attempts have been made to explain
the apparent superiority of GlcN. sulfate over GlcN.HCl by
suggesting that the sulfate anion is limiting in the circulation13
and therefore may provide an oral ‘‘boost’’ to chondroitinTable I
GlcN pharmacokinetics
Formulation Single dose
mg/kg/day
Animal Route
GlcN.HCl 350 Rat i.v., i.p. or o
GlcN.HCl 1600 Guinea Pig Oral
Combination of GlcN.HCl,
Chondroitin Sulfate
and MnAscorbate
375 Rabbit Oral
GlcN.HCl 100 Rabbit Oral
Combination of GlcN.HCl,
Chondroitin Sulfate
214 Dog i.v/p.o
GlcN.HCl 20 Horse i.v. or n.g
GlcN.SO4 20 Horse i.v. or n.g
GlcN.HCl 20 Horse i.v. or n.g.
GlcN.HCl 125 Horse Oralsulfate synthesis14e16. This argument also appears ﬂawed18
because the Km for the sulfate transporters in chondro-
cytes19 has beenmeasured at about 16 mM, a concentration
that is about 50-times the serum sulfate concentration of
0.3 mM12. This means that ingestion of 1.5 g of GlcN.sulfate
would need to increase the serum sulfate concentration
about 50-fold to have any effect on sulfate supply, a change
which appears to be impossible. In contrast, GlcN-3-sulfate,
an ester in which the sulfate group is covalently bound to
the hydroxyl group on carbon-3 of the hexosamine, is explic-
itly not present in the GlcN sulfate sold for joint health and
should not be considered as an oral supplement. It is there-
fore critically important to clearly deﬁne the chemical struc-
ture of compounds used both in vivo and in vitro in all future
research planning.The pharmacokinetics of oral GlcN salts
We have selected for review only pharmacokinetic data
from oral dosing with clinically-approved GlcN preparations.
Search strategies included a PubMed review using the
following search terms: (GlcN.HCl, GlcN.sulfate, OA, thera-
peutic, human, horse, pharmacokinetics). Eight studies of hu-
mans (Table II) and three equine studies (Table III) were
identiﬁed. The horse studies are in general agreement that
the Cmax (at 2 h) is about 10 mM. In one horse study the
Cmax of the sulfate and chloride salts of GlcN were directly
compared and found to be essentially identical. In the
human studies (see Table II for formulation, dose and route,
number of individuals studied, days of dosing before evaluat-
ing the Cmax, Cmax observed and the GlcN assay used), the
Cmax was determined to be between 1 and 4 h after ingestion
in all cases. Importantly, in the six human studies with GlcN,
sulfate salt themeanCmax valueswere consistent with the re-
sult in the one study that employed the hydrochloride salt 81.
Four of the human studies (a total of 62 subjects) were per-
formed in independent laboratories under essentially identi-
cal conditions (a single oral dose of GlcN sulfate given to
normal volunteers at 20 mg/kg, which translates to a single
1500 mgdose of GlcN in a 75 kg individual). TheCmax results
(mostly determined by mass spectroscopy) of these four
studies were remarkably similar at 12,9,10 and 11 mM. Signif-
icantly, one group studied OA patients instead of normal and
in this case themeanCmaxwas7mM.As the literature onCmax
in humans is remarkably consistent, at about 10 mM, it seems
reasonable that no further research is necessary in this area.
Indeed any future use of animal models (Table III) without
a conﬁrmed Cmax ofw10 mM seems unlikely to yield useful
information about potential GlcN effects in humans.II
: animal studies
Days of
dosing
Cmax Serum/Plasma
assay
Reference
ral 1 105 89 mM HPLC 74
e 1400 mM e 75
e 5170 mM e 76
e <45 mM e 22
e 42 mM e 17
1 50 mM or 1 mM LC/MS/MS 78
1 50 mM or 1 mM LC/MS/MS 78
1 300 mM or 1 mM FACE 79
1 60 mM HPLC 80
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explants in vitro
A collection of 29 published articles in this area is shown
in Table I, but may not be exhaustive. The table provides
the concentration range of GlcN salt tested. For reasons
cited in preceding sections, concerning potential clinical rel-
evance, we conﬁne our discussion to those in vitro studies
which have described effects at concentrations close to the
physiologically relevant Cmax of w10 mM. In the ﬁrst of
these studies40, human OA chondrocytes were incubated
with GlcN sulfate at concentrations ranging from 0.2 to
200 mM. Under those conditions, messenger RNA
(mRNA) and protein levels of aggrecan core protein were
increased with a concomitant decrease in the production
and enzymatic activity of matrix metalloproteinase (MMP)-
3. Signiﬁcant effects were detected at 10 mM and above.
In the second, using equine chondrocytes and synovial
cells, GlcN.HCl at about 1 mM, was found to decrease inter-
leukin (IL)-1 stimulated production of PGEs in both cell
types47. Since similar effects on inhibition of enzymes of
the prostaglandin synthase pathway (essential fatty acid
conversion to membrane-intercalated arachidonic acid
and cyclooxygenase (COX)-1/2 conversion of arachidonic
acid to prostaglandins D, E and F), were seen with higher
concentrations of GlcN salts (Table 1, Refs 29, 45, 50,
57, 64, 65, 67, 72), a focus of future research could be on
mechanisms by which extracellular GlcN salts might inter-
fere with this pathway. For example, extracellular GlcN salts
might interfere with the receptors for E series of prostaglan-
dins (EP receptors) required for prostaglandin uptake and
the attendant pro-inﬂammatory effects29. Conversely, extra-
cellular GlcN salts might directly regulate synthesis or trans-
location of Glycosylphosphatidylinositol (GPI)-anchored
proteins on the cell surface; this is a particularly interesting
possibility since GPI-anchored heparan sulfate-substituted
proteins on the cell surface have been shown to directly ac-
tivate PGE229, or promote arachidonic acid release by Se-
cretory phospholipase A2 (sPLA2s)30. Additional studies
(Table I), albeit at supra-physiologic concentrations,
showed changes in gene expression or secretion of pro-in-
ﬂammatory factors such as inducible nitric oxide synthase
(iNOS), endothelial nitric oxide synthase (eNOS), COX-2,
or prostaglandin E (PGE). These effects include suppres-
sion of u-plasminogen activator (u-PA) and MMP2/9,
inhibition of NO and sulfated glycosaminoglycan (GAG) re-
lease, inhibition of gene expression of eNOS, iNOS, COX-2
and secretion of PGE, or inhibition of nuclear factor kappa B
(NFkB) activity. In related studies, others have observed in
chondrocyte pellet cultures, a GlcN salt-mediated inhibition
of IL-1-induced PGE-2 synthase and mPGEs, blockade of
the inhibitory effects of methyl prednisolone, reduced
PLA2 activity and stimulated PG synthesis.In vivo studies of GlcN salts in animal models
of OA
There is a substantial literature focused on the effects of
GlcN in animal models, including the combination of GlcN
and chondroitin sulfate. This includes a number of studies
which employed doses that markedly exceeded those
used in humans, studies with a perceived conﬂict of inter-
est, and studies of the in vivo effects of GlcN on non-artic-
ular diseases. In general, the Cmax for GlcN in these animal
studies was not determined making it difﬁcult to evaluate
therapeutic relevance for human OA.Relevant animal models include lapine, murine and ca-
nine studies. Using an anterior cruciate ligament deﬁcient
model of acute OA in the rabbit and daily GlcN.HCl dosing
for 8 weeks, starting 3 weeks after surgery, Tiraloche, et al.
failed to detect any signiﬁcant effect for most of their out-
comes20. However, the investigators noted that there was
mild protection of the articular cartilage from surface ﬁbrilla-
tion and loss of Saffranin O staining in the lateral tibial pla-
teau, as well as a reduction in biochemically measured
sulfated GAG loss from the femoral condyles. While the
lack of agreement between the site-speciﬁc effects revealed
by histology vs biochemical sulfated GAG analysis was not
resolved, this paper highlighted the importance of examin-
ing site-speciﬁcity in the joint and such ﬁndings are clearly
relevant to human clinical evaluation. The paper also em-
phasizes the need for more quantiﬁable measures of effects
at the biological level. Interestingly, a continuation of this
study reported that oral GlcN may partially inhibit the high
bone turnover induced by ligament transection21, again
highlighting the importance of evaluating multiple tissues
in the joint rather than restricting attention to the cartilage.
The authors21 acknowledged that the major limitation of
the study in extrapolating to human disease is the rapidity
of onset in the model; nonetheless, the results remain rele-
vant to possible mechanistic effects of oral GlcN on joint
health. Using a different model, chymopapain-induced joint
damage in the rabbit, it has been reported that oral GlcN re-
sulted in increased cartilage GAG content in both damaged
and control knees22. Although this model of cartilage dam-
age may not be relevant to human OA, it suggests that oral
GlcN can have a signiﬁcant effect on cellular biosynthetic
activity under conditions of rapid exogenously-mediated
proteolytic GAG depletion from cartilage. Similar results
were reported in a murine model, in which oral GlcN admin-
istered at 100 mg/kg following intra-articular injection of pa-
pain into murine knee joints signiﬁcantly improved cartilage
proteoglycan content at 2 weeks. In addition, the peak con-
centration of serum pro-inﬂammatory cytokines induced by
papain injection occurred earlier and decreased sooner in
the GlcN.HCl supplemented group. This trend was also
seen in expression of these same factors by the liver. More-
over, in this experiment GlcN did not alter the percentage of
mesenteric lymph node lymphocyte populations but accel-
erated their activation. Hence, oral GlcN appears to alter
the physiology of the liver and mesenteric lymph nodes,
which in turn, could indirectly alter the biology of damaged
joints23.GlcN salts and treatment of clinical OA
Reports suggesting that GlcN may be useful clinically for
the treatment of OA have been available since the 1960’s
and controlled clinical trials of oral, parenteral, and topical
preparations abound, yet claims of GlcN’s efﬁcacy as
a pain palliative and as a structure modifying agent for
OA remain highly controversial. The US National Institutes
of Health had intended to settle these issues with the Glu-
cosamine/Chondroitin Intervention Trial (GAIT) study31,
which was a well-powered non-industry ﬁnanced random-
ized double-blind controlled trial comparing GlcN to chon-
droitin sulfate to a combination of both, and included both
placebo and positive control (celecoxib) arms. Although
the primary outcomes of the trial were unambiguously
null, some subgroups appeared to have signiﬁcant positive
effects. In addition, various editorialists have argued that
the GlcN preparation that was tested by the GAIT
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results might have been obtained if a different preparation
(GlcN.sulfate) had been employed in the trial32,33 (see dis-
cussion of the chemistry of these formulations above). Sev-
eral well-performed meta-analyses have been performed in
the last decade, and two recent yet contradictory publica-
tions are representative34,35. Interestingly, they agree that
preparations of GlcN crystallized as the hydrochloride salt
are ineffective, but disagree over the therapeutic beneﬁt of
GlcN preparations crystallized as the sulfate salt. The Co-
chrane Collaboration’s update of its systematic review of
GlcN in OA concluded that whereas GlcN.HCl appears to
be ineffective, studies that focused on the Rottapharm cor-
poration’s preparation of GlcN.sulfate suggest that this
preparation of GlcN is signiﬁcantly more effective than pla-
cebo for treating pain and function in OA35. These results
are in contrast to those of Vlad et al.34 who also considered
the different GlcN preparations separately; they reported
that whereas there is sufﬁcient evidence that the GlcN.HCl
preparation lacks efﬁcacy for pain relief, the heterogeneity
of trials assessing GlcN.sulfate prevents a clear conclusion
regarding efﬁcacy, though the heterogeneity appeared to be
most prominent in industry-sponsored trials of GlcN.sulfate 34.
Interestingly, all published trials that were not industry spon-
sored have been negative, including a recent evaluation of
GlcN sulfate for use in hip OA36. This uncertainty regarding
therapeutic efﬁcacy has been perpetuated by the controlled
studies published after completion of these meta-analyses;
hence, an industry-sponsored study reported that GlcN sul-
fate delayed OA progression to arthroplasty37 whereas the
non-industry sponsored study of hip OA failed to detect any
symptomatic or structural beneﬁts36.
It is not our purpose to provide a deﬁnitive ruling regard-
ing whether GlcN truly has a role in OA therapy; rather, our
intention is to clarify what is known and to distinguish those
areas that we believe warrant further research from others
for which additional public research expenditures would
be unlikely to substantively affect either our understanding
or the societal use of GlcN. In that light, the following issues
should be considered:GlcN SALT FORMULATION FOR CLINICAL USEThere appears to be consensus that GlcN.HCl lacks efﬁ-
cacy for the palliation of pain or function in OA34,35. The tox-
icity proﬁle appears benign, however, and the preparation
appears to be safe for oral consumption. As discussed in
a previous paragraph, the term ‘‘GlcN sulfate’’ is ambigu-
ous, and may refer to a variety of chemical substances. It
is therefore essential to be clear what is under consideration
when discussing the results of clinical trials. The sulfate es-
ter of GlcN (GlcN-3S ester), while retaining a variety of bio-
logical activities, is not a natural oral supplement and is not
generally consumed as a therapeutic or adjunctive agent in
clinical settings, nor have there been any randomized clini-
cal trials of its effect in humans. In contrast, the substance
commonly referred to as ‘‘GlcN sulfate’’ is the sulfate salt of
GlcN, and as noted previously, this GlcN is pharmacologi-
cally identical to the GlcN prepared as the hydrochloride
salt. Moreover, there is good experimental evidence that
the sulfate salt by itself is biologically inactive in vivo regard-
ing articular structures. Hence, although the possibility of
clinical advantages conferred by the GlcN sulfate salt over
the GlcN hydrochloride salt remains, there is at present
no biological or known rational justiﬁcation to explain such
a putative beneﬁt; as such, the burden of proof must rest
on those who argue for such an advantage either to identifya reasonable mechanism of action or to demonstrate an un-
ambiguous empirical advantage. It is useful to bear in mind
that (1) the apparent advantages of GlcN.sulfate vs GlcN
HCl rest entirely on the results of trials sponsored by the
manufacturer of that proprietary preparation whereas all in-
dependent studies have been negative, (2) there appears to
be publication bias in this ﬁeld38, and (3) the more recent
publications tend to be less positive than the older trials35,
which may possibly be related to the recent requirement
by most journals that clinical trials be publicly registered
prior to their initiation. Therefore, we conclude that whereas
the sulfate salt of GlcN appears in meta-analyses to offer
possible efﬁcacy for OA therapy, there is insufﬁcient mech-
anistic rationale or independent empirical evidence at pres-
ent to consider it to be substantively different than the
hydrochloride salt of GlcN.INTERPRETATION OF CLINICAL TRIAL DATASkepticism is warranted in the interpretation of meta-anal-
yses that survey issues for which incomplete information is
available. Underlying the meta-analytic method is the as-
sumption that aggregating information from multiple studies
should strengthen the power to discern actual effects. How-
ever, where the available data differ substantially from the
total data collected, such as in cases of signiﬁcant publica-
tion bias, meta-analyses may falsely elevate an apparent
effect that might have disappeared altogether if all of the ev-
idence were able to be considered; in extreme cases where
only positive results are published, the apparent (though not
necessarily real) clinical beneﬁt would be greatly magniﬁed
by meta-analysis. We therefore counsel caution in interpret-
ing meta-analyses that assess therapeutic agents that have
not been clearly independently evaluated, or for which clear
publication bias exists.Research perspective: GlcN salts and OA
management
There remains controversy concerning the rational role, if
any, of GlcN in OA management. Nonetheless, analyses of
public behavioral patterns suggest that consumption of oral
supplements perceived to be beneﬁcial does not change in
response to evidence of lack of efﬁcacy, whereas consump-
tion clearly declines in response to evidence of signiﬁcant
toxicity. Indeed, for GlcN, publication of the GAIT data33
garnered a great deal of publicity concerning the failure to
detect clinical efﬁcacy, however US sales remained con-
stant in the months afterwards without any noticeable de-
cline39. Therefore, in light of the apparent safety of oral
GlcN preparations, as long as they are manufactured using
Good Manufacturing Practice, it is likely that most con-
sumers ﬁnd the presence or absence of clinical evidence
demonstrating efﬁcacy to be irrelevant. This suggests that
additional trials to elucidate groups for which GlcN might
be efﬁcacious will have little impact on public attitudes or
behavior, and substantial outlays of scarce public research
dollars for these purposes will not likely affect the public’s
approach to OA.
GlcN salts have been shown to be potent modulators
of the hexosamine biosynthetic pathway and downstream
O-glycosylation reactions in in vitro systems. However,
these effects are only achieved with extracellular concentra-
tions in the mM range, which are 100e1000 fold higher than
extracellular concentrations achieved in vivo in joint ﬂuid
and tissues. Therefore, future research aimed at elucidating
10 J. A. Block et al.: Oral glucosamine in osteoarthritismechanisms of action of GlcN salts for translational pur-
poses need to be based on use of (1) standardized in vitro
cell and tissue culture systems, (2) well characterized ani-
mal models of OA pathology, (3) therapeutically relevant
preparations and concentrations of GlcN salts and (4) stan-
dardized outcome measures that include the inﬂammatory
and pain pathways relevant to human OA.
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